Incidence of end-stage renal disease among live kidney donors

被引:135
作者
Fehrman-Ekholm, Ingela [1 ]
Norden, Gunnela [1 ]
Lennerling, Annette [1 ]
Rizell, Magnus [1 ]
Mjornstedt, Lars [1 ]
Wramner, Lars [1 ]
Olausson, Michael [1 ]
机构
[1] Sahlgrens Univ Hosp, Dept Transplantat & Liver Surg, SE-41345 Gothenburg, Sweden
关键词
living kidney donors; end-stage renal disease; incidence; ethics donation; nephrosclerosis;
D O I
10.1097/01.tp.0000250728.73268.e3
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. The increasing use of living kidney donors requires knowledge about long-term effects, especially number and causes of donors with end-stage renal disease (ESRD). Methods. A retrospective data analysis of 1, 112 consecutive living kidney donors who under-went nephrectomy from 1965 until 2005 at Sahlgrenska University Hospital. Case reports were sought with help from nephrologists in the region and data from Swedish Registry of Active Uremic Treatment (SRAU). Results. The number of cases with end stage kidney failure among living kidney donors was 6/1112, that is 0.5%. The donors had reached ESRD during the years 2001-2006, that means 36-41 years after start of the living donor program. The donors were 45-89 years old, median 77 years, and five of six were males. Time since donation was 14-27 years, median 20 years, for the donors developing ESRD. The diagnoses were nephrosclerosis (4 cases), postrenal failure (1 case), and renal carcinoma (1 case). The expected incidence for development of ESRD according to incidence in the general population would have been two donors but we found six. However, considering the high age of the donors in this follow up, the age-matched incidence is calculated to be closer to six donors due to higher incidence in the aged. Conclusion. In all 0.5% of the donors developed ESRD. Due to high age of the uremic donors, there seems to be no increased incidence.
引用
收藏
页码:1646 / 1648
页数:3
相关论文
共 6 条
[1]  
CECKA JM, 2001, CLIN TRANSPLANTS 200, P5
[2]   No evidence of accelerated loss of kidney function in living kidney donors:: Results from a cross-sectional follow-up [J].
Fehrman-Ekholm, I ;
Dunér, F ;
Brink, B ;
Tydén, G ;
Elinder, CG .
TRANSPLANTATION, 2001, 72 (03) :444-449
[3]   LONG-TERM EFFECTS OF REDUCED RENAL MASS IN HUMANS [J].
KASISKE, BL ;
MA, JZ ;
LOUIS, TA ;
SWAN, SK .
KIDNEY INTERNATIONAL, 1995, 48 (03) :814-819
[4]   Higher risk for renal failure in first-degree relatives of white patients with end-stage renal disease: A population-based study [J].
O'Dea, DF ;
Murphy, SW ;
Hefferton, D ;
Parfrey, PS .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (05) :794-801
[5]   Does treated primary hypertension lead to end-stage renal disease? A 20-year follow-up of the Primary Prevention Study in Goteborg, Sweden [J].
Siewert-Delle, A ;
Ljungman, S ;
Andersson, OK ;
Wilhelmsen, L .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 1998, 13 (12) :3084-3090
[6]  
STEINER RW, 2004, ED EVALUATING SELECT, P51